Short-term hormone therapy after radiation treatment had a comparable effect on overall survival and disease-specific survival as longer-course therapy in men with intermediate-risk prostate cancer, according to a study presented at a meeting of the American Society for Radiation Oncology. In the study of 133 patients, disease-specific survival was 96% for both short- and long-term hormone therapy groups while 10-year overall survival was 61% in the shorter-course group and 65% in the long-term group.

Related Summaries